energyraters
I know in the economic evaluation they talked about a $23 USD cost for FebriDx which likely included the cost to administer as well as the test, so $15 USD sounds about right and is fairly close to a rapid test.
Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States | Published in Journal of Health Economics and Outcomes Research (jheor.org)
According to their analysis there is likely around 154 million ARI (Acute Respiratory Infection) cases each year in the U.S. If we take a typical 20-30% profit margin for a device e.g. $5 profit per test, then we are looking at around $770 million profit annually for the U.S. alone as a potential market for both hospital and private health care visits.
This device has big potential.
The re-rate journey, page-8
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
0.001(3.13%) |
Mkt cap ! $15.88M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.3¢ | 3.2¢ | $25.29K | 778.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6806 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 321904 | 1 |
View Market Depth
| Last trade - 14.56pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
3.3¢ |
Change
0.001 ( 3.13 %) |
||||
| Open | High | Low | Volume | ||
| 3.2¢ | 3.3¢ | 3.2¢ | 167763 | ||
| Last updated 14.56pm 14/06/2024 ? | |||||
| LDX (ASX) Chart |